and cell therapies. the company’s platforms have generated nine first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. its lead biologic product candidate is anktiva, an fda-approved immunotherapy in combination with bacillus calmette-guérin...
and distributes specialty pharmaceutical products and therapies. the company offers autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology, and ophthalmology; immunotherapy and neonatal respiratory critical care therapies, analgesics and gastrointestinal products. the...
(OTC:TPIV) is a clinical-stage immunotherapy specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of oncology and infectious disease. The Company is also exploiting the emerging field of vaccinomics for the development of vaccines applica...
Gold The Fall of the House of Gold Contributed Opinion (05/07/2025) Rick Mills of Ahead of the Herd once again interviews Bob Moriarty of 321Gold, speaking about current events and sharing some investment ideas. Base MetalsGoldCritical Metals ...
Compugen's COM701 (anti-PVRIG) Demonstrates Preliminary Durable Anti-Tumor Activity in Triple Immunotherapy Combination in Patients with Recurrent Metastatic MSS Endometrial Cancer (PR Newswire)+6.67% Jun-02-23 07:09AM We Think Compugen (NASDAQ:CGEN) Needs To Drive Business Growth Carefully ...
The company uses autologous cell therapies, RNA and DNA-based immunotherapy, and small molecules for developing its drugs. Regen Biopharma announced a two-for-one stock split of its common shares, effective November 4. Nano Labs Ltd. (NA) –China-based Nano Labs Ltd. is a fabless IC (...
Ideas Top Analyst Stocks Popular Top Smart Score Stocks Popular Top Insiders Stocks Research Tools Compare Stocks Compare ETFs Trending Stocks Daily Analyst Ratings Daily Insiders Trades Dividend Stocks ETF Center Top Gainers/losers/active ETFs Calculators Dividend Calculator Options Profit Calculator Dollar...
Celgene, Jounce Therapeutics in early cancer immunotherapy development pact Celgene continues to sprinkle cash around the biotech sector, tying up with smaller companies for first-dibs access to potentially valuable drugs and technologies. CELGAGIOJUNO Latest Stock Market News & Data Jun 20, 2016 10:...
Corvus Pharma initiates a Phase I study of a novel immunotherapy approach for coronavirus patients. CRVS Stock Investing News, Analysis and Tips Jun 29, 2016 1:28 PM EDT 16 Biopharma Companies Besides Medivation That Are Attractive Targets Besides Sanofi, Biogen is the next most likely to comple...
Cue Biopharma Presents New Positive Data from Ongoing Phase 1 Trial of CUE-101 in Combination with KEYTRUDA(R) for Recurrent/Metastatic HPV+ Head and Neck Cancer at the Society for Immunotherapy of Cancers (SITC) 37th Annual Meeting (GlobeNewswire)+6.48% ...